RCAG
CORT icon

Rehmann Capital Advisory Group’s Corcept Therapeutics CORT Stock Holding History

Rehmann Capital Advisory Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-51
Closed -$681 – 2096
2018
Q4 		$681 Hold
51
– – ﹤0.01% 1716
2018
Q3 		$715 Sell
51
-136
-73% -$1.9K ﹤0.01% 2038
2018
Q2 		$2.94K Sell
187
-42
-18% -$731 ﹤0.01% 1686
2018
Q1 		$4K Buy
+229
New +$4.24K ﹤0.01% 1552

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Rehmann Capital Advisory Group's CORT Position: Q1 2019 in Review

Rehmann Capital Advisory Group sold out of Corcept Therapeutics (CORT) in Q1 2019, closing a stake of 51 shares — an estimated $681 sold.

Rehmann Capital Advisory Group first reported a position in CORT in Q1 2018 and held it in 4 quarters. The position peaked at $4K in Q1 2018. 208 funds tracked by Wall St. Rank hold CORT as of Q1 2019.

  • Rehmann Capital Advisory Group reported no remaining Corcept Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Rehmann Capital Advisory Group sold 51 Corcept Therapeutics shares in Q1 2019, an estimated $681.
  • Rehmann Capital Advisory Group first reported a position in Corcept Therapeutics in Q1 2018 and held it in 4 quarters.
  • Rehmann Capital Advisory Group's Corcept Therapeutics position peaked at $4K in Q1 2018.
  • 208 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q1 2019, filed 22 May 2019.